Search Results - "Li, Chunze"

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology by Liu, Stephanie N., Li, Chunze

“…Antibody–drug conjugates (ADCs) are important molecular entities in the treatment of cancer. These conjugates combine the target specificity of monoclonal…”
Get full text

Techno-economic analysis of optimal hybrid renewable energy systems – A case study for a campus microgrid by Wong, Shen Yuong, Li, Chunze

“…People are becoming more aware of the benefits of renewable energy. In recent years, a lot of research deals with the use of energy systems during on-grid or…”
Get full text

Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates? by Liao, Michael Z., Lu, Dan, Kågedal, Matts, Miles, Dale, Samineni, Divya, Liu, Stephanie N., Li, Chunze

“…Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the cytotoxicity of a chemical agent. They represent a rapidly evolving area of…”
Get full text

Acyl-CoA thioesters as chemically-reactive intermediates of carboxylic acid-containing drugs by Grillo, Mark P., Li, Chunze, Benet, Leslie Z.

“…Several carboxylic acid-containing drugs have been withdrawn from clinical use due to adverse drug reactions including idiosyncratic hepatotoxicity and…”
Get full text

COLREGs-Compliant Unmanned Surface Vehicles Collision Avoidance Based on Multi-Objective Genetic Algorithm by Ning, Jun, Chen, Hanmin, Li, Tieshan, Li, Wei, Li, Chunze

“…Autonomous ships or Unmanned Surface Vehicles (USV) collision avoidance and path planning problems among multi-vessels are investigated in this paper. Firstly,…”
Get full text

Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization by Hamed, Salaheldin, Li, Chunze, Liao, Michael Z., Warwick, Lorna, Zhou, Zhu

Get full text

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma by Shemesh, Colby S., Agarwal, Priya, Lu, Tong, Lee, Calvin, Dere, Randall C., Li, Xiaobin, Li, Chunze, Jin, Jin Y., Girish, Sandhya, Miles, Dale, Lu, Dan

“…Purpose The phase Ib/II open-label study (NCT01992653) evaluated the antibody-drug conjugate polatuzumab vedotin (pola) plus rituximab/obinutuzumab,…”
Get full text

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma by Lu, Dan, Lu, Tong, Shi, Rong, Gibiansky, Leonid, Agarwal, Priya, Shemesh, Colby S., Dere, Randall C., Ogbu, Uzor, Hirata, Jamie, Chanu, Pascal, Girish, Sandhya, Jin, Jin Yan, Li, Chunze, Miles, Dale

“…Purpose The established two-analyte integrated population pharmacokinetic model was applied to assess the impact of intrinsic/extrinsic factors on the…”
Get full text

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study by Wang, Bei, Deng, Rong, Hennig, Stefanie, Badovinac Crnjevic, Tanja, Kaewphluk, Monika, Kågedal, Matts, Quartino, Angelica L., Girish, Sandhya, Li, Chunze, Kirschbrown, Whitney P.

“…Purpose To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous…”
Get full text

Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies by Li, Chunze, Zhang, Cindy, Li, Zao, Samineni, Divya, Lu, Dan, Wang, Bei, Chen, Shang-Chiung, Zhang, Rong, Agarwal, Priya, Fine, Bernard M, Girish, Sandhya

“…vc-MMAE antibody-drug conjugates (ADCs) consist of a monoclonal antibody (mAb) covalently bound with a potent anti-mitotic toxin (MMAE) through a…”
Get full text

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma by Shi, Rong, Lu, Tong, Ku, Grace, Ding, Hao, Saito, Tomohisa, Gibiansky, Leonid, Agarwal, Priya, Li, Xiaobin, Jin, Jin Yan, Girish, Sandhya, Miles, Dale, Li, Chunze, Lu, Dan

“…Purpose The CD79b-targeted antibody–drug conjugate polatuzumab vedotin (pola), alone and with chemoimmunotherapy, has clinical efficacy and a tolerable safety…”
Get full text

Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling by Chen, Yuan, Ma, Fang, Jones, Nicholas, Deng, Rong, Li, Chunze, Li, Chi‐Chung

“…Mosunetuzumab is a CD3/CD20 bispecific antibody. As an on‐target effect, transient elevation of interleukin‐6 (IL‐6) occurs in early treatment cycles. A…”
Get full text

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma by Sandhu, Shahneen, McNeil, Catriona M., LoRusso, Patricia, Patel, Manish R., Kabbarah, Omar, Li, Chunze, Sanabria, Sandra, Flanagan, W. Michael, Yeh, Ru-Fang, Brunstein, Flavia, Nazzal, Denise, Hicks, Rodney, Lemahieu, Vanessa, Meng, Raymond, Hamid, Omid, Infante, Jeffrey R.

“…Summary Background Endothelin B receptor (ET B R) is involved in melanoma pathogenesis and is overexpressed in metastatic melanoma. The antibody-drug conjugate…”
Get full text

Pharmacokinetics of biologics in gastric cancer by Li, Junyi, Turner, David C., Li, Feifei, Chen, Xi, Liao, Michael Z., Li, Chunze

“…Gastric cancer (GC) remains one of the leading causes of cancer death worldwide despite improvements in therapeutic options. Several biologics have been…”
Get full text

Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study by Wang, Bei, Deng, Rong, Hennig, Stefanie, Badovinac Crnjevic, Tanja, Kaewphluk, Monika, Kågedal, Matts, Quartino, Angelica L., Girish, Sandhya, Li, Chunze, Kirschbrown, Whitney P.

Get full text

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma by Bender, Brendan, Li, Chi‐Chung, Marchand, Mathilde, Turner, David C., Li, Feifei, Vadhavkar, Shweta, Wang, Bei, Deng, Rong, Lu, James, Jin, Jin, Li, Chunze, Yin, Shen, Wei, Michael, Chanu, Pascal

“…Mosunetuzumab (Mosun) is a CD20xCD3 T‐cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. The approved step‐up dose…”
Get full text

Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX by Liao, Michael Z., Deng, Rong, Gibiansky, Leonid, Lu, Tong, Agarwal, Priya, Dere, Randall, Lee, Calvin, Hirata, Jamie, Herbaux, Charles, Salles, Gilles, Li, Chunze, Miles, Dale

“…This ethnic sensitivity analysis used data from the phase III POLARIX study (NCT03274492) to assess polatuzumab vedotin pharmacokinetics (PKs) in Asian versus…”
Get full text

Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216 by WALLS, Marlena, BAXI, Sangita M, YIN, Min-Jean, MEHTA, Pramod P, LIU, Kevin K.-C, JINJIANG ZHU, ESTRELLA, Heather, CHUNZE LI, ZIENTEK, Michael, QING ZONG, SMEAL, Tod

“…Constitutive activation of phosphoinositide 3-kinase (PI3K) occurs frequently in many human tumors via either gene mutation in the p110α catalytic subunit of…”
Get full text

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study by Deng, Rong, Gibiansky, Leonid, Lu, Tong, Flowers, Christopher R., Sehn, Laurie H., Liu, Qi, Agarwal, Priya, Liao, Michael Z., Dere, Randall, Lee, Calvin, Man, Gabriel, Hirata, Jamie, Li, Chunze, Miles, Dale

“…Polatuzumab vedotin is a CD79b‐directed antibody–drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE). The…”
Get full text

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma by Lu, Dan, Lu, Tong, Gibiansky, Leonid, Li, Xiaobin, Li, Chunze, Agarwal, Priya, Shemesh, Colby S., Shi, Rong, Dere, Randall C., Hirata, Jamie, Miles, Dale, Chanu, Pascal, Girish, Sandhya, Jin, Jin Yan

“…A two‐analyte integrated population pharmacokinetic (PK) model that simultaneously describes concentrations of antibody‐conjugated monomethyl auristatin E…”
Get full text